C56887 Identifying High Carbon Footprint Medicines In The NHS

Contract summary

Industry

• General management consultancy services - 79411000

• Environmental impact assessment other than for construction - 90711000

• Environmental issues consultancy services - 90713000

Location of contract

LS2 7UE

Value of contract

£50,000

Procurement reference

CF-0520900D0O000000rwimUAA1

Published date

9 December 2021

Closing date

14 January 2022

Closing time

12pm

Contract start date

31 January 2022

Contract end date

30 April 2022

Contract type

Service contract

Procedure type

Open procedure (below threshold)

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Yes

---

Description

The 2019 NHS Long Term Plan set sustainability commitments for the NHS, which are elaborated in the 'Delivering a Net Zero National Health Service' report.
Medicines account for 25% of NHS carbon emissions, 5 percentage points being direct emissions, e.g. from inhalers and anaesthetic gases, and 20% being from other medicines, including those emissions embedded in the medicines supply chain.
Whilst several options exist, it is unclear which methodology is the most practical and usable for the NHS in assessing the carbon footprint of specific medicines, which is essential for determining the next steps in the NHS's strategy to reduce emissions from medicines, particularly those beyond direct emissions from inhalers and anaesthetics.
The objective of this project is therefore to understand the best approach to assess carbon emissions from specific medicines or groups of medicines (e.g. by class, formulation, administration route), and then use this to inform the next priority areas for the sustainable medicines programme, as well as recommendations for future monitoring of progress.
Indicative phasing

1. Phase 1: Review of available evidence

2. Phase 2: Discussion in the form of one or several advisory group(s), with participation from key subject matter experts and stakeholders from academia, clinical practice, medicine regulation and industry.

3. Phase 3: Developing recommendations. Building on the findings from Phases 1 and 2, and discussions with the NHS England and NHS Improvement team.
Essential skills should include:-1. Experience in conducting research, including literature reviews, in relevant subjects such as environmental impact and healthcare.
2. Experience in recruiting and moderating high profile advisory groups.
3. Experience in synthesising findings to engage with and make the appropriate recommendations to external bodies.
4. Skills and experience in analysis/(health) economics, and an indication on how this would support collaboration across groups - e.g. environmental and economics/analysis.
We would welcome responses brought together by a collaboration of one or more suppliers to cover the range of expertise and skills required to deliver this work
Interested suppliers should register on the NHS England & Improvement e-procurement system here: https://health-family.force.com/login

• Once logged in click 'Find Opportunities' and search for C56887 Identifying High Carbon Footprint Medicines in the NHS.
• Click 'Register Interest'
• Once you have registered your interest you will be able to view the Requirements and submit a response to the questions within the portal.
• Any messages about the opportunity should be sent via the e-procurement system using the Clarification Log in the "Suppliers Documents" section. You can do this by going to the home page and:
o Click on 'My proposals & Quotes'
o Click the relevant Project Title
o Click 'Messages' & 'New Message'

---

About the buyer

Contact name

Andrew Powell

Address

Quarry House
Leeds
LS2 7UE
United Kingdom

Telephone

07702433551

Email

andrew.powell14@nhs.net